Evidence map›Paper›PMID 31620680›Full record

ArticleEuropean journal of breast health2019

Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast.

Mustafa Gök, Uğur Topal, Bahadır Öz, Hülya Akgün, Alper Celal Akcan, Erdoğan Mütevelli Sözüer

Open access · diamondAbstract read
In one paragraph

Article in European journal of breast health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mustafa GökDepartment of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0003-4272-1087
Uğur TopalDepartment of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0003-1305-2056
Bahadır ÖzDepartment of Pathology, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0002-3791-0521
Hülya AkgünDepartment of Surgical Oncology, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0002-9249-4153
Alper Celal AkcanDepartment of Pathology, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0001-9469-4274
Erdoğan Mütevelli SözüerDepartment of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey.ORCID 0000-0002-3332-2570
Erciyes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThere are multiple subtypes of breast cancer with different biological and pathological features and accordingly exhibit different clinical behaviors. The aim of this study was to compare the treatment modalities, clinical features and prognostic characteristics of Mix Mucinous Carcinomas (MMBC) and other rare tumors of the breast. MATERIALS AND

methodA total of 2152 patients who were operated on for breast cancer in our clinic between 2010-2019, with pathological diagnoses of tubular, pure mucinous, mix mucinous or papillary carcinoma were enrolled in the study. Patients were divided into two groups as mix mucinous patients (Group1) and other rare tumors (Group2). The demographic, clinical and prognostic characteristics and treatment approaches were compared between Groups, and additionally between the subtypes of Group 2.

results42 patients participated in our study. Group 1 consisted of 7 patients, and Group2 consisted of 35 patients. The subtypes in Group2 were papillary (n=21), pure mucinous (n=10) and tubular (n=4). Progesterone Receptor Positivity was found to be significantly higher in Group 2 patients than in Group1 patients (p=0.005, p<0.05). Multicentricity rates in the tumors of the patients in Group1 were found to be statistically significantly higher than the patients in Group 2 (p=0.024, p<0.05). In subtype analysis in Group2, there were no statistically significant differences parameters in the subgroups (p>0.05). Mean survival was 19.5+5.6 (8.5-30.5) months in Group 1 and 46.3+5.2 (36.1-56.6) months, in Group2 when evaluated separately (p:0.002).

conclusionThe prognosis of pure mucinosis (PMBC) and other atypical cancers of the breast compared to the (MMBC) is quite good. Rare pathological types of breast cancer can have favorable outcomes when treated with necessary oncological principles.

Indexed as

Breast neoplasmsmix mucinous breast carcinomapure mucinous breast carcinoma

Identifiers

PMID31620680
PMCPMC6776130
OpenAlexW2978528232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.